# PP-0231 — Treatment-related Toxicity and Supportive Care — QA Report

**Artifact:** `04_QA_REPORT.md`  
**Version:** v1.0.0  
**Status:** GOLD — READY FOR INTEGRATION

---

# 1. QA Executive Determination

**Overall result: PASS — GOLD — READY FOR INTEGRATION**

The artifact set was produced from the Approved + Locked PP-0231 Decision Batch.

No scope reopening was performed.

The QA review confirms:

- four-artifact architecture;
- Source-First evidence basis;
- Gold-depth adherence;
- locked-decision integrity;
- clinical safety;
- patient-facing educational integrity;
- adjacent-PP boundary integrity;
- Knowledge Graph connectivity;
- evidence traceability;
- cross-artifact consistency;
- package naming and ZIP integrity.

---

# 2. Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| PP identity correct | PASS | PP-0231 title preserved exactly. |
| Primary clinical question preserved | PASS | Toxicity recognition, assessment and supportive management remain central. |
| Core scope preserved | PASS | Cross-modality toxicity/supportive-care layer implemented. |
| Included domains complete | PASS | Chemotherapy, radiotherapy, targeted therapy, immunotherapy and supportive management represented. |
| Acute/chronic distinction | PASS | Both are explicitly addressed. |
| Assessment architecture | PASS | Recognition → assessment → severity → management represented. |
| Prevention/prophylaxis | PASS | Included at conceptual and evidence-supported level. |
| Treatment-modification interface | PASS | Delay/modification/cessation included without individualized prescribing. |
| Long-term toxicity | PASS | Included without absorbing survivorship/follow-up. |
| Patient education | PASS | Dedicated patient explanation and questions included. |
| Misconceptions | PASS | Dedicated myths/facts section included. |
| Knowledge Graph | PASS | Upstream, related and downstream relationships included. |
| Boundary | PASS | Core/Supporting/Excluded/Delegated structure preserved. |

---

# 3. Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Disease-specific evidence used | PASS | NCCN/NCI/ACS gastric-cancer materials used. |
| General toxicity framework | PASS | ESMO-ASCO 2023 used as principal framework. |
| Chemotherapy toxicity | PASS | GI, hematologic, neurologic and other domains represented conservatively. |
| Radiation toxicity | PASS | Gastric radiation toxicity supported by ACS. |
| Targeted therapy toxicity | PASS | Representative gastric targeted therapies included without becoming drug monographs. |
| Immunotherapy toxicity | PASS | Immune-related toxicity explicitly represented. |
| Toxicity vs progression | PASS | Differential interpretation included. |
| Treatment modification | PASS | Presented as clinician decision principle, not patient instruction. |
| Individualization safeguard | PASS | No individualized diagnosis/prescription. |
| Uncertainty preserved | PASS | Exact management remains treatment/context dependent. |
| Safety escalation | PASS | Patient directed to treatment team rather than unsupported universal thresholds. |
| Long-term effects | PASS | Included with survivorship/follow-up boundary. |

---

# 4. Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain-language explanation | PASS | Technical concepts are explained before/with terminology. |
| Patient-facing depth | PASS | Dedicated explanation, messages and questions included. |
| Logical progression | PASS | Definition → recognition → assessment → management → modification → long-term effects. |
| Common misconceptions | PASS | Multiple clinically important myths addressed. |
| Practical usefulness | PASS | Patient questions and safety principles included. |
| Avoids overpromising | PASS | No claim that toxicity can always be prevented or predicted. |
| Encourages clinician discussion | PASS | Real-world decisions delegated to treating team. |
| Appropriate uncertainty | PASS | Cause, severity and treatment response are not inferred automatically. |
| Atomicity | PASS | Package remains toxicity/supportive-care focused. |
| Patient safety boundary | PASS | No self-directed treatment changes. |

---

# 5. Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| Approved Decision Batch respected | PASS | PP-0231 locked scope implemented without reopening. |
| Source-First rule respected | PASS | PP-specific clinical Source Files were searched before production. |
| Gold Discussion reference used | PASS | Approved discussion example used for structure/depth. |
| Gold artifact structure | PASS | Four required artifacts produced. |
| Absolute Gold-depth rule | PASS | No compacted executive-summary substitution. |
| CKO structure | PASS | Gold CKO architecture preserved. |
| Knowledge Passport structure | PASS | Gold Passport architecture preserved. |
| Evidence Package structure | PASS | Evidence matrix and traceability preserved. |
| QA depth | PASS | Substantive multi-layer QA performed. |
| Boundary structure | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP. |
| User-controlled sequence | PASS | No automatic selection of next PP. |
| Artifact naming | PASS | Standard names preserved. |
| ZIP packaging | PASS | Single ZIP containing all four artifacts. |

---

# 6. Clinical Safety Review

| Safety Item | Result | QA Note |
|---|---|---|
| No individualized diagnosis | PASS | General education only. |
| No individualized treatment prescription | PASS | No patient-specific treatment recommendation. |
| No instruction to stop treatment | PASS | Treatment modification presented as clinician decision. |
| No individualized dose calculation | PASS | Explicitly excluded. |
| No universal emergency threshold | PASS | Contact instructions remain treatment-team/context dependent. |
| Immunotherapy toxicity appropriately bounded | PASS | No full steroid/immune-suppression protocol reproduced. |
| CTCAE appropriately bounded | PASS | Grading concept included, full table excluded. |
| Differential diagnosis preserved | PASS | Toxicity is not assumed from symptom alone. |
| Toxicity vs progression preserved | PASS | Explicitly addressed. |
| Supportive care correctly framed | PASS | Does not imply treatment failure. |

---

# 7. Patient Misconception Review

## Misconception A

“Side effects prove treatment is working.”

**Status:** PASS — explicitly corrected.

## Misconception B

“Severe side effects mean stronger anti-cancer effect.”

**Status:** PASS — explicitly corrected.

## Misconception C

“Every symptom during treatment is caused by treatment.”

**Status:** PASS — differential causes explained.

## Misconception D

“Supportive care means active treatment has failed.”

**Status:** PASS — corrected.

## Misconception E

“I should stop treatment if I develop side effects.”

**Status:** PASS — clinician-decision boundary explicit.

## Misconception F

“Immunotherapy toxicity is the same as chemotherapy toxicity.”

**Status:** PASS — distinctive immune-related toxicity explained.

---

# 8. Adjacent PP Overlap Audit

| Adjacent PP | Audit Result | Boundary |
|---|---|---|
| PP-0203 Perioperative Chemotherapy | PASS | Treatment strategy upstream; toxicity downstream. |
| PP-0204 FLOT | PASS | Regimen identity upstream; detailed toxicity delegated to PP-0231. |
| PP-0207 Chemoradiation | PASS | Combined-modality strategy upstream; toxicity owned here. |
| PP-0209 Targeted Therapy | PASS | Targeted-treatment modality upstream; toxicity owned here. |
| PP-0210 HER2-targeted Therapy | PASS | HER2 treatment upstream; T-DXd/trastuzumab toxicity management interface here. |
| PP-0211 CLDN18.2-targeted Therapy | PASS | Treatment strategy upstream; toxicity/support here. |
| PP-0212 Anti-angiogenic Therapy | PASS | Anti-angiogenic treatment upstream; toxicity management here. |
| PP-0213 Immunotherapy | PASS | Immunotherapy strategy upstream; toxicity here. |
| PP-0214 ICI | PASS | ICI treatment upstream; immune-toxicity management here. |
| PP-0215 MSI-H/dMMR immunotherapy | PASS | Biomarker/treatment context upstream; toxicity here. |
| PP-0216 PD-L1-guided immunotherapy | PASS | Biomarker-guided treatment upstream; toxicity here. |
| PP-0227 Palliative Care | PASS | Palliative-care architecture remains separate. |
| PP-0228 Best Supportive Care | PASS | Broad BSC remains separate. |
| PP-0229 Survivorship | PASS | Survivorship remains separate. |
| PP-0230 Long-term Follow-up | PASS | Follow-up process remains separate. |
| PP-0232 Multidisciplinary Management | PASS | Overall MDT architecture remains separate. |

---

# 9. Evidence Traceability Audit

| Evidence Domain | Traceability | Result |
|---|---|---|
| General toxicity management | ESMO-ASCO 2023 | PASS |
| Toxicity grading | ESMO-ASCO 2023 | PASS |
| Prophylaxis | ESMO-ASCO 2023 | PASS |
| Patient-reported toxicity | ESMO-ASCO 2023 | PASS |
| Multidisciplinary care | ESMO-ASCO 2023 | PASS |
| Treatment modification | ESMO-ASCO 2023 | PASS |
| Gastric chemotherapy toxicity | ACS/NCI/NCCN | PASS |
| Gastric radiation toxicity | ACS | PASS |
| Targeted therapy | NCI/NCCN/ACS | PASS |
| Immunotherapy toxicity | NCCN/ESMO-ASCO/ACS | PASS |
| Long-term effects | NCCN/ACS | PASS |

---

# 10. Numerical Evidence Audit

No numerical toxicity threshold is used as a universal patient instruction.

No unsupported dose, frequency or individualized threshold has been introduced.

**Result: PASS**

---

# 11. Knowledge Graph Audit

### Prerequisites

Treatment packages are represented as upstream nodes.

### Current PP

PP-0231 is the toxicity/supportive-management node.

### Related

Palliative care, BSC, survivorship, long-term follow-up and MDT are linked without ownership duplication.

### Downstream

Treatment modification, long-term follow-up and survivorship interfaces are represented.

### Delegation

Detailed treatment-specific and specialty protocols are delegated.

**Result: PASS**

---

# 12. Gold Depth Integrity Review

The project rule states:

> Gold Reference Depth = Minimum Standard.

The package was therefore not designed as a short executive summary.

Depth checks:

- CKO: full educational architecture — PASS.
- Knowledge Passport: full runtime/governance architecture — PASS.
- Evidence Package: evidence matrix + detailed notes + limitations + gaps + traceability — PASS.
- QA: multi-layer substantive review — PASS.
- Knowledge Graph: explicit prerequisite/related/downstream/delegated structure — PASS.
- Patient-facing depth: explanation + misconceptions + questions + safety — PASS.

**Result: PASS — GOLD DEPTH PRESERVED**

---

# 13. Source-First Audit

The PP-specific Source Files were searched before artifact generation.

Primary sources identified include:

- NCCN Gastric Cancer;
- ESMO-ASCO 2023;
- NCI Treatment of Stomach Cancer;
- NCI Gastric Cancer Treatment PDQ;
- ACS chemotherapy;
- ACS stomach cancer/radiation;
- ACS immunotherapy.

**Result: PASS**

No essential clinical claim was intentionally substituted with unsupported generic knowledge.

---

# 14. Locked Decision Integrity

The user explicitly stated that all PP-0231 Decision Batch decisions were:

**Approved + Locked.**

The artifact package:

- does not reopen the Decision Batch;
- does not introduce a competing scope;
- preserves the recommended core;
- preserves exclusions;
- preserves delegation;
- preserves adjacent boundaries.

**Result: PASS**

---

# 15. Cross-artifact Consistency

| Element | CKO | Passport | Evidence | QA | Result |
|---|---|---|---|---|---|
| PP identity | ✓ | ✓ | ✓ | ✓ | PASS |
| Core scope | ✓ | ✓ | ✓ | ✓ | PASS |
| Exclusions | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Source-first | ✓ | ✓ | ✓ | ✓ | PASS |
| Safety | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Version | v1.0.0 | v1.0.0 | v1.0.0 | v1.0.0 | PASS |

---

# 16. Package Integrity

Required artifact set:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

All four are present, non-empty and packaged in one PP-specific directory and ZIP.

**Result: PASS**

---

# 17. Final QA Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
